Karachi: First National Equities Limited (FNEL) has reported a financial loss for the fiscal year ending June 30, 2025, amidst a strategic transformation aimed at repositioning the company into a high-growth, Sharia-compliant enterprise. The financial statement, disclosed on November 26, 2025, reveals significant changes in the company’s assets and liabilities as it transitions towards pharmaceutical manufacturing and technology enablement.
The company’s non-current assets include strategic long-term investments and other assets totaling 1.07 billion rupees. Meanwhile, current assets, comprising cash, trade receivables, and other financial instruments, amounted to 1.85 billion rupees. Total assets were reported at 2.67 billion rupees.
On the liabilities side, FNEL’s non-current liabilities were noted at 1.51 billion rupees, with current liabilities, including trade payables and provisions, summing up to 1.14 billion rupees. The total liabilities stood at 2.67 billion rupees, matching the total assets, indicating a balanced financial position.
The company’s financial performance for the fiscal year highlights an operating revenue of 33.92 million rupees. However, FNEL incurred a loss before levies and taxation of 71.39 million rupees, and a loss after income tax of 78.68 million rupees. This represents a noticeable increase from the previous year’s loss after income tax of 51.47 million rupees. The loss per share was recorded at 0.29 rupees, compared to 0.19 rupees in the prior year.
According to information available from the Pakistan Stock Exchange (PSX), FNEL’s shares have been significantly impacted by the reported financial loss. The comprehensive loss for the year, after accounting for an unrealized gain in the market value of investments, summed to 44.16 million rupees. This reflects FNEL’s ongoing efforts to enhance shareholder value through strategic shifts despite the current financial setback.
FNEL is advancing into a future focused on sustainable, high-quality earnings and meaningful shareholder value. The company’s board is committed to this strategic transformation, anticipating growth in the pharmaceutical and technology sectors. This move is designed to align with the long-term vision of establishing FNEL as a Sharia-compliant enterprise, poised to leverage emerging opportunities in high-growth industries.